Financings in Brief: PharmaTarget
This article was originally published in The Gray Sheet
PharmaTarget: Minneapolis-based firm raises $1.8 mil. in private placement of 446,000 units, each consisting of two shares of common stock and one warrant to purchase one share of common stock. Proceeds will support development of PharmaTarget's lead product, the Implantable Pharmacologic Atrioverter (IPA). The IPA is a drug infusion system that can be programmed "to sense fibrillation of the atrial chambers of the heart and then automatically deliver a predetermined dose of a prescribed drug directly to the heart to treat the condition," PharmaTarget says. The company anticipates introduction of its system "sometime in 1999"...
You may also be interested in...
Officials from the US Food and Drug Administration cited their reasons for refusing to review new applications for companies with unresolved data integrity failures.
However, Vaccinex sees possible efficacy for SEMA4D inhibition in later-stage Huntington’s as well as Alzheimer’s disease. Pepinemab is also being studied with Keytruda in head-and-neck cancer.
In last year’s acquisition, Bristol Myers Squibb agreed to pay Celgene investors another $9 per share based on three approvals, including idecabtagene vicleucel (bb2121) by 30 March 2021.